$1.11
0.000.00%
At close: -
$1.11
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Ikena Oncology Analyst Ratings and Price Targets | NASDAQ:IKNA | Benzinga
Ikena Oncology Inc has a consensus price target of $10.25 based on the ratings of 4 analysts. The high is $22 issued by HC Wainwright & Co. on March 17, 2023. The low is $2 issued by Wedbush on May 29, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Wedbush on November 11, 2024, August 12, 2024, and May 29, 2024, respectively. With an average price target of $3.33 between HC Wainwright & Co., HC Wainwright & Co., and Wedbush, there's an implied 200.30% upside for Ikena Oncology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Credit Suisse
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Ikena Oncology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/11/2024 | Buy Now | 260.36% | HC Wainwright & Co. | Andres Maldonado41% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 260.36% | HC Wainwright & Co. | Andres Maldonado41% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 05/29/2024 | Buy Now | 80.18% | Wedbush | David Nierengarten60% | $8 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 05/29/2024 | Buy Now | 260.36% | HC Wainwright & Co. | Andres Maldonado41% | $11 → $4 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 620.72% | Wedbush | David Nierengarten60% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2024 | Buy Now | 890.99% | HC Wainwright & Co. | Andres Maldonado41% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 890.99% | HC Wainwright & Co. | Andres Maldonado41% | $11 → $11 | Maintains | Buy | Get Alert |
| 01/19/2024 | Buy Now | 620.72% | Wedbush | David Nierengarten60% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 01/19/2024 | Buy Now | 890.99% | HC Wainwright & Co. | Andres Maldonado41% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 890.99% | HC Wainwright & Co. | Andres Maldonado41% | $18 → $11 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | 890.99% | Wedbush | David Nierengarten60% | → $11 | Initiates | → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 1521.62% | HC Wainwright & Co. | Andres Maldonado41% | → $18 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 1521.62% | HC Wainwright & Co. | Andres Maldonado41% | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 1521.62% | HC Wainwright & Co. | Andres Maldonado41% | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 1071.17% | Credit Suisse | Judah Frommer66% | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 1521.62% | HC Wainwright & Co. | Andres Maldonado41% | → $18 | Assumes | → Buy | Get Alert |
| 03/17/2023 | Buy Now | 1881.98% | HC Wainwright & Co. | Robert Burns41% | → $22 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 1071.17% | Credit Suisse | Judah Frommer66% | $16 → $13 | Maintains | Outperform | Get Alert |
| 11/29/2022 | Buy Now | 1341.44% | Credit Suisse | Judah Frommer66% | $18 → $16 | Maintains | Outperform | Get Alert |
| 11/29/2022 | Buy Now | 1881.98% | HC Wainwright & Co. | Robert Burns41% | $26 → $22 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 1521.62% | Credit Suisse | Judah Frommer66% | $20 → $18 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | 1701.8% | Credit Suisse | Judah Frommer66% | $24 → $20 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Ikena Oncology (IKNA) stock?
The latest price target for Ikena Oncology (NASDAQ:IKNA) was reported by HC Wainwright & Co. on November 11, 2024. The analyst firm set a price target for $4.00 expecting IKNA to rise to within 12 months (a possible 260.36% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ikena Oncology (IKNA)?
The latest analyst rating for Ikena Oncology (NASDAQ:IKNA) was provided by HC Wainwright & Co., and Ikena Oncology reiterated their buy rating.
When was the last upgrade for Ikena Oncology (IKNA)?
There is no last upgrade for Ikena Oncology
When was the last downgrade for Ikena Oncology (IKNA)?
The last downgrade for Ikena Oncology Inc happened on May 29, 2024 when Wedbush changed their price target from $8 to $2 for Ikena Oncology Inc.
When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.
Is the Analyst Rating Ikena Oncology (IKNA) correct?
While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a reiterated with a price target of $4.00 to $4.00. The current price Ikena Oncology (IKNA) is trading at is $1.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
